Brief: Acorda Therapeutics Q4 Non-GAAP Loss Per Share $0.67
09/03/2022 21:55
March 9 (Reuters) - Acorda Therapeutics Inc ACOR.O :
* SEES FY AMPYRA REVENUE $68 MILLION TO $78 MILLION
* Q4 AMPYRA REVENUE $22.5 MILLION VERSUS $25.3 MILLION
* ACORDA THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR
2021
FINANCIAL RESULTS
* Q4 NON-GAAP LOSS PER SHARE $0.67
* Q4 GAAP LOSS PER SHARE $1.73
Further company coverage: ACOR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Acorda Therapeutics
See all newsBrief: Acorda TherapeuticsCourt Held Hearing To Consider Approval Of Sale Of Substantially All Of Co's Assets To Merz Pharmaceuticals Under Asset Sale
Brief: Acorda Says Debtors Did Not Receive More Than One Qualified Bid Before Bid Deadline, In Connection With Chapter 11 Proceedings
Live Markets: Biotech companies in 'Darwinian' world as cash remains king
U.S. FDA declines to approve Supernus' drug-device combination for Parkinson's disease (updated)
U.S. FDA declines to approve Supernus' drug-device combination for Parkinson's disease